Katherine V. Ferry‐Galow

Topoisomerase 1 and DNA damage: Pharmacodynamic responses and mechanism of trastuzumab deruxtecan in HER2- expressing advanced solid tumors.

Deborah Wilsker, Sarah Shin, Geraldine Helen O'Sullivan Coyne, Angie B. Dull et autres

us (code pays fourni par la source)

HER2-independent antitumor and pharmacodynamic responses to trastuzumab deruxtecan in patients with advanced solid tumors.

Sarah Shin, Geraldine Helen O'Sullivan Coyne, Jared C. Foster, Elizabeth Katherine Lee et autres

us (code pays fourni par la source)

Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update

Alice P. Chen, Christina L. Rosenberger, Nancy Moore, Jared C. Foster et autres

us (code pays fourni par la source)

Abstract CT259: Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors (RARE CANCER) trial (RARE 3): Tiragolumab + Atezolizumab

Amanda Walker, Naoko Takebe, Murielle Hogu, Sarah J. Shin et autres

us, my (code pays fourni par la source)

NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer

Margaret C. Wheless, Shannon Stockton, Heloisa P. Soares, Farshid Dayyani et autres

us (code pays fourni par la source)

Phase 1 clinical trial of the ataxia telangiectasia and Rad3‐related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)

Liza C. Villaruz, Jingxiao Jin, Hong Wang, James J. Lee et autres

us (code pays fourni par la source)

Abstract A006: Biomarker analyses of WEE1 inhibition in patients with refractory CCNE1 amplified solid tumors

Siqing Fu, Camila Bragança Xavier, Khanda Keyomarsi, Yan Wang et autres

us (code pays fourni par la source)

Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia–Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors

Geraldine O’Sullivan Coyne, T. Khanh, Shivaani Kummar, Sarina A. Piha‐Paul et autres

us (code pays fourni par la source)

Supplementary Figure S3 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors

Sarah J. Shin, Geraldine O’Sullivan Coyne, Shivaani Kummar, Sarah B. Miller et autres

Supplementary Table S8 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors

Sarah J. Shin, Geraldine O’Sullivan Coyne, Shivaani Kummar, Sarah B. Miller et autres

Supplementary Table S3 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors

Sarah J. Shin, Geraldine O’Sullivan Coyne, Shivaani Kummar, Sarah B. Miller et autres

Supplementary Table S1 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors

Sarah J. Shin, Geraldine O’Sullivan Coyne, Shivaani Kummar, Sarah B. Miller et autres